Positive Interim Analysis from Medicus Pharma Ltd
Medicus Pharma Ltd. (NASDAQ: MDCX) has recently shared exciting interim results from its SKNJCT-003 Phase 2 clinical study, which focuses on a non-invasive approach to treat basal cell carcinoma (BCC) of the skin. This news marks a significant milestone as the company aims to revolutionize the treatment options available for BCC.
Overview of the SKNJCT-003 Study
The SKNJCT-003 study is taking place across nine clinical sites in the United States and seeks to enroll a total of 60 patients. Remarkably, the interim analysis was performed after more than half of these patients were enrolled and randomized. Early indications suggest a promising outcome, with over 60% of the subjects achieving complete clinical clearance.
Details of the Interim Analysis
The results so far indicate that the investigational product, D-MNA, has been well tolerated across all participants, with no reports of serious adverse events or dose-limiting toxicities. Two different dosage levels have been evaluated: a low-dose group receiving 100 micrograms (ug) of D-MNA and a high-dose group receiving 200 ug. Importantly, no systemic effects were noted, and the findings have been reassuring regarding laboratory parameters, vital signs, ECGs, and physical examinations.
Future Plans with the FDA
Encouraged by these results, Medicus Pharma Ltd plans to present the interim analysis to the United States Food and Drug Administration (FDA) in order to request a Type C meeting. This meeting is essential for discussing the development of the D-MNA product and aligning on future clinical pathways, with hopes to fast-track the development program moving forward.
Insights from the Executive Team
Dr. Raza Bokhari, Executive Chairman & CEO, expressed his optimism regarding the interim results, stating, “We are immensely encouraged by the positively trending interim analysis. This brings us one step closer to delivering a novel, non-invasive treatment for BCC.” Such leadership enthusiasm reflects the company’s commitment to innovate within the oncology space.
Understanding the Clinical Trial Design
The SKNJCT-003 clinical trial is set to be a double-blind, placebo-controlled study aimed at a balanced comparison of efficacy between D-MNA and a placebo control. Participants will be randomly assigned to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group of 100?g D-MNA, or a high-dose group of 200?g D-MNA.
Previous Study Insights
In a prior Phase 1 study (SKNJCT-001) completed earlier, D-MNA was similarly well tolerated across 13 enrolled participants, achieving a primary objective of safety and tolerability. This earlier study also highlighted the efficacy of D-MNA, with six participants showing complete response, meaning the BCC could not be histologically detected in final excisions. Notably, all individuals demonstrating complete responses had the nodular subtype of BCC.
Expanding Clinical Efforts Globally
In addition to the U.S. efforts, Medicus Pharma Ltd. has submitted a clinical design (SKNJCT-004) to the UAE Department of Health. This new endeavor targets the randomization of 36 patients across four prominent sites in the UAE, including Cleveland Clinic Abu Dhabi and American Hospital of Dubai, expanding the reach of their innovative therapies.
Company Contact Information
For further inquiries, you may contact the following representatives:
Carolyn Bonner, President
(610) 636-0184
cbonner@medicuspharma.com
Jeremy Feffer
LifeSci Advisors
(212) 915-2568
jfeffer@lifesciadvisors.com
About Medicus Pharma Ltd
Medicus Pharma Ltd. (NASDAQ: MDCX) is a pioneering company in the biotech and life sciences space, dedicated to advancing clinical programs for transformative therapeutic assets. More specifically, its subsidiary, SkinJect Inc., focuses on developing an innovative, non-invasive treatment for basal cell carcinoma utilizing a patented dissolvable microneedle patch to effectively deliver chemotherapeutic agents.
Frequently Asked Questions
What is the purpose of the SKNJCT-003 clinical study?
The SKNJCT-003 study aims to evaluate the efficacy and safety of D-MNA, a novel non-invasive treatment for basal cell carcinoma.
How many patients are involved in the SKNJCT-003 study?
The study is expected to randomize a total of 60 patients across nine clinical sites.
What results did the interim analysis show?
Over 60% of subjects achieved complete clinical clearance, with D-MNA being well tolerated with no serious adverse events reported.
What is the next step for Medicus Pharma Ltd regarding the FDA?
The company plans to present the interim analysis to the FDA and request a Type C meeting to discuss the clinical development pathway.
What previous studies has D-MNA undergone?
Prior to SKNJCT-003, D-MNA was tested in the Phase 1 study (SKNJCT-001), which confirmed its safety and tolerability across participants.
